The present invention relates to a composition for prevention or treatment of gynecological diseases containing an extract of Sarcodon imbricatus as an active ingredient. Specifically, the extract of Sarcodon imbricatus of the present invention can be effectively used, with only one dose, for prevention or treatment of gynecological diseases by treating dysmenorrhea, reducing a menstrual period, an amount of menstruation, menstrual irregularity, and extravasated blood, and clearing the color of menstruation.

Systems and methods for performing Direct Sodium Removal (DSR) therapy are provided in which an implantable device includes a pump coupled to an inlet catheter designed for placement in a patient's peritoneal cavity, an outlet catheter designed to be coupled to the patient's bladder, and is operably coupled to an analyte sensor, the pump programmed to transfer and/or cease transfer of fluid from the patient's peritoneal cavity to the patient's bladder for voiding responsive to a level of analyte detected by the analyte sensor. In addition, the system may include a processor that computes an amount of analyte transferred per pumping session.

Systems and methods for performing Direct Sodium Removal (DSR) therapy are provided in which an implantable device includes a pump coupled to an inlet catheter designed for placement in a patient's peritoneal cavity, an outlet catheter designed to be coupled to the patient's bladder, and is operably coupled to an analyte sensor, the pump programmed to transfer and/or cease transfer of fluid from the patient's peritoneal cavity to the patient's bladder for voiding responsive to a level of analyte detected by the analyte sensor. In addition, the system may include a processor that computes an amount of analyte transferred per pumping session.

Systems and methods for performing Direct Sodium Removal (DSR) therapy are provided in which an implantable device includes a pump coupled to an inlet catheter designed for placement in a patient's peritoneal cavity, an outlet catheter designed to be coupled to the patient's bladder, and is operably coupled to an analyte sensor, the pump programmed to transfer and/or cease transfer of fluid from the patient's peritoneal cavity to the patient's bladder for voiding responsive to a level of analyte detected by the analyte sensor. In addition, the system may include a processor that computes an amount of analyte transferred per pumping session.

The present invention refers to a method for the synthesis of a biodegradable calcium release material that shows controlled ion release properties for tissue engineering, biomaterials containing the calcium particles as well as the calcium particles obtainable therefrom. By varying the treatment temperature of the described method, the calcium material shows different calcium release profiles. Contrary to a specific chemical composition such as CaCO.sub.3 which is associated to a specific calcium release profile, the present invention allows a manifold of compositions, with a manifold of calcium release profiles, all starting from a single specific chemical composition calcium precursor. Therefore, the invention also relates to the use of the controllable release, calcium material in tissue regeneration such as wound healing processes.

A seal formulation for forming a physical barrier in the teat canal of a non-human animal for prophylactically controlling infection of a mammary gland by a mastitis-causing organism comprises a polymer in a gel base wherein the polymer is a lower alkyl vinyl ether-maleic anhydride copolymer or a salt derivative thereof. The lower alkyl vinyl ether-maleic anhydride copolymer salt derivative may comprise at least one cationic ion including monovalent, bivalent or trivalent cations and mixtures thereof.

A seal formulation for forming a physical barrier in the teat canal of a non-human animal for prophylactically controlling infection of a mammary gland by a mastitis-causing organism comprises a polymer in a gel base wherein the polymer is a lower alkyl vinyl ether-maleic anhydride copolymer or a salt derivative thereof. The lower alkyl vinyl ether-maleic anhydride copolymer salt derivative may comprise at least one cationic ion including monovalent, bivalent or trivalent cations and mixtures thereof.

A seal formulation for forming a physical barrier in the teat canal of a non-human animal for prophylactically controlling infection of a mammary gland by a mastitis-causing organism comprises a polymer in a gel base wherein the polymer is a lower alkyl vinyl ether-maleic anhydride copolymer or a salt derivative thereof. The lower alkyl vinyl ether-maleic anhydride copolymer salt derivative may comprise at least one cationic ion including monovalent, bivalent or trivalent cations and mixtures thereof.

The present invention is directed to a method of treatment, including prevention or reducing the likelihood of adverse effects of chemotherapy comprising reducing and/or inhibiting chemotherapy-induced adverse effects (CIAE), especially central nervous system adverse effects, such as cognitive effects (especially chemotherapy induced cognitive impairment or CICI, also referred to as reduced cognition, cognitive impairment or chemobrain) by administering to the patient in need, including co-administering to the subject in need a pharmaceutically effective amount of a protein kinase C (PKC, often, PKC α and/or β) inhibitor, alone or in combination with a lithium salt. Related pharmaceutical compositions are also provided by the present invention.

The present invention is directed to a method of treatment, including prevention or reducing the likelihood of adverse effects of chemotherapy comprising reducing and/or inhibiting chemotherapy-induced adverse effects (CIAE), especially central nervous system adverse effects, such as cognitive effects (especially chemotherapy induced cognitive impairment or CICI, also referred to as reduced cognition, cognitive impairment or chemobrain) by administering to the patient in need, including co-administering to the subject in need a pharmaceutically effective amount of a protein kinase C (PKC, often, PKC α and/or β) inhibitor, alone or in combination with a lithium salt. Related pharmaceutical compositions are also provided by the present invention.